1O - Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab

Date 12 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session PD-L1 expression and tumor microenvironment in advanced lung cancer
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Giulia Mazzaschi
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors G. Mazzaschi1, F. Facchinetti2, D. Madeddu1, S. Buti2, F. Gelsomino3, A. Ardizzoni4, F. Aversa1, G. Missale1, F. Quaini1, M. Tiseo1
  • 1Medicine And Surgery, Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 2Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 3Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4Policlinico S. Orsola-Malpighi, 40138 - Bologna/IT


To define prognostic and potentially predictive immune profiles in NSCLC patients receiving nivolumab, an integrated analysis of tissue and circulating parameters was performed.